Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase

British Journal of Cancer

Volumn 109, Issue 6, 2013, Pages 1556-1561

  Shpilberg, O ^a   Jackisch, C ^b  

^a RABIN MEDICAL CENTER   (Israel)

^b Klinikum Offenbach GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; PREDNISONE; RECOMBINANT HYALURONIDASE; RITUXIMAB; TRASTUZUMAB; VINCRISTINE;

ABDOMINAL PAIN; ACNE; AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; BREAST CANCER; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ASSESSMENT; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FOLLICULAR LYMPHOMA; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; IMMUNOGENICITY; INDUCTION CHEMOTHERAPY; INFECTION; INFUSION RELATED REACTION; INJECTION SITE; INJECTION SITE DISCOMFORT; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; INJECTION SITE SWELLING; MAINTENANCE THERAPY; MONOTHERAPY; MUSCULOSKELETAL PAIN; NONHUMAN; PRIORITY JOURNAL; RASH; SINGLE DRUG DOSE; SUBCUTANEOUS DRUG ADMINISTRATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; HYALURONOGLUCOSAMINIDASE; INJECTIONS, SUBCUTANEOUS; LYMPHOMA, FOLLICULAR; MALE; RECOMBINANT PROTEINS;

EID: 84884587259     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.371     Document Type: Article

References (33)

1. Assouline S, Buccheri V, Delmer A, Doelken G, Gaidano G, McIntyre C, Brewster M, Hourcade-Potelleret F, Sayyed P, Badoux X (2012) Subcutaneous rituximab in combination with fludarabine and cyclophosphamide for patients with CLL: Initial results of a phase Ib study (SAWYER [BO25341]) show non-inferior pharmacokinetics and comparable safety to that of intravenous rituximab. Blood 120: Abstract 1637.
2. Bookbinder LH, Hofer A, Haller MF, Zepeda ML, Keller GA, Lim JE, Edgington TS, Shepard HM, Patton JS, Frost GI (2006) A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release 114: 230-241.
3. Chan AL, Leung HW, Lu CL, Lin SJ (2009) Cost-effectiveness of trastuzumab as adjuvant therapy for early breast cancer: A systematic review. Ann Pharmacother 43: 296-303.
4. Davies A, Merli F, Mihaljevik B, Siritanaratkul N, Solal-Céligny P, Boehnke A, Berge C, McIntyre C, Barrett M, Macdonald D (2012) Pharmacokinetics (PK), safety and overall response rate (ORR) achieved with subcutaneous (SC) administration of rituximab in combination with chemotherapy were comparable to those achieved with intravenous (IV) administration in patients (pts) with follicular lymphoma (FL) in the first-line setting: Stage 1 results of the phase III SABRINA study (BO22334). Blood 120: Abstract 1629.
5. Del Nagro CJ, Mao CP, Brovarney M (2010) Comparison of B cell depletion mediated by intravenous (IV) Rituxan and Rituxan given subcutaneous (SC) in cynomolgus monkeys. Blood 116: Abstract 3980.
6. F. Hoffmann-La Roche Mab Thera Smpc. 2008 http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000165/WC500025821.pdf Accessed 3/10/2011
7. F. Hoffmann-La Roche. Herceptin SmPC (2011) http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000278/WC500074922.pdf. (Accessed 14/10/2011
8. Gilbert D, Cothran D (2005) SC versus IV delivery: Reducing costs while increasing patient satisfaction. Hematol Oncol News Issues. December 25-27. Available from URL http://www.towniecentral.com/Hemonctown/Magazine.aspx. (Accessed 23/05/2013
9. Haller MF (2007) Converting intravenous dosing to subcutaneous dosing with recombinant human hyaluronidase. Pharm Tech http://www.pharmtech.com/pharmtech/article/articleDetail.jsp?id=463578. (Accessed 28/01/2012
10. Harb G, Lebel F, Battikha J, Thackara JW (2010) Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers. Curr Med Res Opin 26: 279-288.
11. Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim SB, Pienkowski T, Lichinitser M, Semiglazov V, Melichar B, Jackisch C (2012) Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): A phase 3, open-label, multicentre, randomised trial. Lancet Oncol 13: 869-878.
12. Kagan L, Turner MR, Balu-Iyer SV, Mager DE (2012) Subcutaneous absorption of monoclonal antibodies: Role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats. Pharm Res 29: 490-499.
13. Lundin J, Kimby E, Bjorkholm M, Broliden PA, Celsing F, Hjalmar V, Möllgård L, Rebello P, Hale G, Waldmann H, Mellstedt H, Osterborg A (2002) Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1 H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100: 768-773.
14. Mager DE, Jusko WJ (2001) General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28: 507-532.
15. National Comprehensive Cancer Network (2012) Clinical practice guidelines in oncology. Non-Hodgkin's lymphoma. http://www.nccn.org/professionals/physician-gls/pdf/nhl.pdf. (Accessed 14/03/2012
16. Perez-Ellis C, Gonclves A, Jacquemier J, Marty M, Girre V, Roché H, Brain E, Moatti JP, Viens P, Le Corroller-Soriano AG (2009) Cost-effectiveness analysis of trastuzumab (Herceptin) in HER2-overexpressed metastatic breast cancer. Am J Clin Oncol 32: 492-498.
17. Salar A, Avivi I, Larouche J-F, Janikova A, Pereira J, Brewster M, Catalani O, McIntyre C, Sayyed P, Haynes A (2012) Final results of the BP22333 study demonstrate non-inferior pharmacokinetics (PK) and safety of subcutaneous (SC) administration of rituximab compared with intravenous (IV) administration as maintenance therapy in patients with follicular lymphoma (FL). Blood 120: Abstract 1641.
18. Salar A, Bouabdallah R, McIntyre C, Sayyed P, Bittner B (2010) A two-stage phase Ib study to investigate the pharmacokinetics, safety and tolerability of subcutaneous rituximab in patients with follicular lymphoma as part of maintenance treatment. Blood 116: Abstract 2858.
19. Salar A, Casao D, Cervera M, Pedro C, Calafell M, Abella E, Alvarez-Larrán A, Besses C (2006) Rapid infusion of rituximab with or without steroidcontaining chemotherapy: 1-yr experience in a single institution. Eur J Haematol 77: 338-340.
20. Sehn LH, Donaldson J, Filewich A, Fitzgerald C, Gill KK, Runzer N, Searle B, Souliere S, Spinelli JJ, Sutherland J, Connors JM (2007) Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. Blood 109: 4171-4173.
21. Selam JL (2010) Evolution of diabetes insulin delivery devices. J Diabetes Sci Technol 4: 505-513.
22. Stilgenbauer S, Zenz T, Winkler D, Bühler A, Schlenk RF, Groner S, Busch R, Hensel M, Dührsen U, Finke J, Dreger P, Jäger U, Lengfelder E, Hohloch K, Söling U, Schlag R, Kneba M, Hallek M, Döhner H. German Chronic Lymphocytic Leukemia Study Group (2009) Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: Clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 27: 3994-4001.
23. Thomas JR, Wallace MS, Yocum RC, Vaughn DE, Haller MF, Flament J (2009) The INFUSE-Morphine study: Use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illness. J Pain Symptom Manage 38: 663-672.
24. Thomas JR, Yocum RC, Haller MF, von Gunten CF (2007) Assessing the role of human recombinant hyaluronidase in gravity-driven subcutaneous hydration: The INFUSE-LR study. J Palliat Med 10: 1312-1320.
25. US FDA (2011) US Department of Health and Human Services. http://www.fda.gov. (Accessed 14/03/2012
26. US NIH (2011) Clinical Trials.gov, http://www.clinicaltrials.gov. (Accessed 14/03/2013
27. Vaughn DE, Yocum RC, Muchmore DB, Sugarman BJ, Vick AM, Bilinsky IP, Frost GI (2009) Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase. Diabetes Technol Ther 11: 345-352.
28. Verzijl N, DeGroot J, Thorpe SR, Bank RA, Shaw JN, Lyons TJ, Bijlsma JW, Lafeber FP, Baynes JW, TeKoppele JM (2000) Effect of collagen turnover on the accumulation of advanced glycation end products. J Biol Chem 275: 39027-39031.
29. Vescia S, Baumgärtner AK, Jacobs VR, Kiechle-Bahat M, Rody A, Loibl S, Harbeck N (2008) Management of venous port systems in oncology: A review of current evidence. Ann Oncol 19: 9-15.
30. Vogel WH (2010) Infusion reactions: Diagnosis, assessment, and management. Clin J Oncol Nurs 14: E10-E21.
31. Wang DD, Zhang S, Zhao H, Men AY, Parivar K (2009) Fixed dosing versus body sized based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol 49: 1012-1024.
32. Wynne C, Harvey V, Schwabe C, Waaka D, McIntyre C, Bittner B (2013) Comparison of subcutaneous and intravenous administration of trastuzumab: A phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer. J Clin Pharmacol 53: 192-201.
33. Yin A, Li J, Hurst D, Visich J (2010) Population pharmacokinetics (PK) and association of PK and clinical outcomes of rituximab in patients with non-Hodgkin's lymphoma. J Clin Oncol 28(Suppl 15s): Abstract e13108.